Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPN1 | P15169 | 3/20 | 0.57 |
| ▸ | CPB2 | Q96IY4 | 3/20 | 0.57 |
| ▸ | SLC6A1 | P30531 | 3/20 | 0.47 |
| ▸ | SLC6A11 | P48066 | 2/20 | 0.47 |
| ▸ | SLC6A13 | Q9NSD5 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | APLNR | P35414 | 2/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25662157 | 1.00 | CPN1 (0.57) | CPN1CPB2SLC6A1SLC6A11SLC6A13 | |
| SCHEMBL25662164 | 1.00 | CPN1 (0.57) | CPN1CPB2SLC6A1SLC6A11SLC6A13 | |
| SCHEMBL5313699 | 0.94 | CPN1 (0.51) | CPN1CPB2SLC6A1SLC6A11SLC6A13 | |
| SCHEMBL27607144 | 0.88 | CPN1 (0.44) | CPN1CPB2SLC6A1SLC6A11SLC6A13 | |
| SCHEMBL31167584 | 0.88 | CPN1 (0.44) | CPN1CPB2SLC6A1SLC6A11SLC6A13 | |
| SCHEMBL29508636 | 0.88 | CPN1 (0.44) | CPN1CPB2SLC6A1SLC6A11SLC6A13 | |
| SCHEMBL5499047 | 0.88 | CPN1 (0.44) | CPN1CPB2SLC6A1SLC6A11SLC6A13 | |
| Hydrochloric Acid SCHEMBL25263972 | 0.86 | CPN1 (0.43) | CPN1CPB2SLC6A1SLC6A11SLC6A13 | |
| Hydrochloric Acid SCHEMBL31603105 | 0.86 | CPN1 (0.43) | CPN1CPB2SLC6A1SLC6A11SLC6A13 | |
| Hydrochloric Acid SCHEMBL29508656 | 0.86 | CPN1 (0.43) | CPN1CPB2SLC6A1SLC6A11SLC6A13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0316809-B1 | Salts of amino-(poly)percarboxylic acids | AUSIMONT SPA (IT) | 1993-11-03 | — | — | EP | claimed |
| CN-113773289-B | Naphthalene [1,2-b ] heterocycle-4, 5-diketone compound and preparation method and application thereof | 沈阳药科大学 | 2023-05-12 | — | — | CN | disclosed |
| CN-113950471-A | Charged ion channel blockers and methods of use thereof | 诺西恩医疗公司 | 2022-01-18 | — | — | CN | disclosed |
| WO-2018021977-A1 | GLYCINE METABOLISM MODULATORS AND USES THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-02-01 | — | — | WO | disclosed |
| US-7569569-B2 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. (US) | 2009-08-04 | — | — | US | disclosed |
| US-7402583-B2 | Substituted quinolines as antitumor agents | ASTRZENCA AB (SE) | 2008-07-22 | — | — | US | disclosed |
| US-20070238721-A1 | Highly Selective Novel Amidation Method | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-10-11 | — | — | US | disclosed |
| US-7220771-B2 | Methods of using indazole derivatives as JNK inhibitors | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-22 | — | — | US | disclosed |
| US-7211594-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-01 | — | — | US | disclosed |
| US-7208513-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-04-24 | — | — | US | disclosed |
| US-5294362-A | Bleach | AUSIMONT S.R.L. (IT) | 1994-03-15 | — | — | US | disclosed |
| EP-0316809-B1 | Salts of amino-(poly)percarboxylic acids | AUSIMONT SPA (IT) | 1993-11-03 | — | — | EP | disclosed |
| US-5245075-A | Bleaching agents | AUSIMONT S.R.L. (IT) | 1993-09-14 | — | — | US | disclosed |
| US-5236678-A | Process for absorption of sulfur compounds from fluids using piperidines | THE DOW CHEMICAL COMPANY (US) | 1993-08-17 | — | — | US | disclosed |
| EP-0552360-A1 | A COMPOSITION AND METHOD FOR SIMULTANEOUS ABSORPTION OF SULFUR DIOXIDE AND NITRIC OXIDE | THE DOW CHEMICAL COMPANY (US) | 1993-07-28 | — | — | EP | disclosed |
| WO-1993003825-A1 | A COMPOSITION AND METHOD FOR SIMULTANEOUS ABSORPTION OF SULFUR DIOXIDE AND NITRIC OXIDE | THE DOW CHEMICAL COMPANY (US) | 1993-03-04 | — | — | WO | disclosed |
| US-5167941-A | Sulfur dioxide; cationic polyelectrolyte stabilizers | THE DOW CHEMICAL COMPANY (US) | 1992-12-01 | — | — | US | disclosed |
| EP-0471592-A2 | Process for absorption of sulfur compounds from fluids using certain piperidines, piperazines, or anhydrides of monocarboxylic amino acids | THE DOW CHEMICAL COMPANY (US) | 1992-02-19 | — | — | EP | disclosed |
| EP-0316809-A2 | Salts of amino-(poly)percarboxylic acids | AUSIMONT S.p.A. (IT) | 1989-05-24 | — | — | EP | disclosed |
| US-4433152-A | ANTIINFLAMMATORY AGENT, ANTIALLERGEN OR ANTICOAGULANT | NIPPON CHEMIPHAR CO., LTD. (JP) | 1984-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238721-A1 | Highly Selective Novel Amidation Method | NAAA, CPS1, COASY | CPN1 286/4885CPB2 559/4885SLC6A1 3877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.